Will Protein A Be the Long-Term Solution for Your Purification Needs? - Biomanufacturers and vendors are now exploring more cost-effective purification technologies. - BioPharm International

ADVERTISEMENT

Will Protein A Be the Long-Term Solution for Your Purification Needs?
Biomanufacturers and vendors are now exploring more cost-effective purification technologies.


BioPharm International
Volume 23, Issue 6

WESTERN EUROPEANS GETTING OUT OF PROTEIN A FIRST


Figure 1. Switching from Protein A usage: US versus Western Europe
In our 7th Annual Report, one of the problems we continue to explore is how respondents are planning to move away from Protein A, and if so, at what stages of manufacturing. This year, it turns out that globally, over 53% are considering alternatives to Protein A to reduce costs in new production projects. However, only 8% will actually be moving away from Protein A for existing production projects over the next 12 months (Figure 1).

Interestingly, though, a much higher proportion of Western European respondents indicated that they are considering alternatives to Protein A. Nearly 77% of Western European biomanufacturers are considering Protein A alternatives to reduce costs. So it appears that Western European facilities may be more ready to switch when the price of alternatives to Protein A are low enough to make switching feasible.

To summarize, chromatography purification steps are having a significant impact on overall capacity today, (with 19% of biomanufacturing facilities considering this step to be a 'significant' or 'severe' bottleneck). Protein A is right there in the middle. But even as options develop and alternatives are approved, because Protein A works, it will likely still be the workhorse in the downstream process for the foreseeable future. In fact, over the next 24 months, 15% of biomanufacturers simply are planning on outsourcing their downstream process operations. But that will be the topic of a future column.

CORRECTION

The April column incorrectly indicated that ADSEPT (ADvanced SEParation Technology) was made by Nysa Membrane Technologies. The company's current name is Natrix Separations Inc.

Eric Langer is president and managing partner at BioPlan Associates, Inc., Rockville, MD. He is also a member of BioPharm International's editorial advisory board 301.921.5979,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here